Genomic Characteristics of Bladder Cancer: An AACR Project GENIE Study.

John Paul Braun, Kenneth A D Palattao, Elijah Torbenson, Beau Hsia, Abubakar Tauseef

Abstract read

In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it

0cells of the map it votes in

2citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

Pan-Cancer Targeted Sequencing Reveals Genomic Heterogeneity and Prognostic Subgroups in Urothelial Bladder Cancer.Cancers · 2026
Article
Effect of co-occurring mutations inFrontiers in immunology · 2026
Article

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

John Paul BraunSchool of Medicine, Creighton University, Omaha, NE 68178, USA.ORCID 0009-0008-7503-5298

Kenneth A D PalattaoSchool of Medicine, Creighton University, Omaha, NE 68178, USA.ORCID 0009-0002-6743-0710

Elijah TorbensonSchool of Medicine, Creighton University, Omaha, NE 68178, USA.

Beau HsiaSchool of Medicine, Creighton University, Phoenix, AZ 85012, USA.ORCID 0009-0009-6403-502X

Abubakar TauseefDepartment of Internal Medicine, School of Medicine, Creighton University, Omaha, NE 68178, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder and urothelial carcinoma are marked by profound genomic diversity. Using a large, multi-institutional dataset, we performed comprehensive genomic profiling of 4631 tumor samples from 4050 individuals. A retrospective analysis of bladder and urothelial cancer was performed using the AACR Project GENIE database. Demographic associations, mutation frequencies, copy number changes, and survival correlations were analyzed with a

Indexed as

Urinary Bladder NeoplasmsAgedDNA-Binding ProteinsDNA Copy Number VariationsFemaleGenomicsHistone DemethylasesHumansMaleMiddle AgedMutationMutation RateNeoplasm ProteinsNuclear ProteinsReceptor, Fibroblast Growth Factor, Type 3Retinoblastoma Binding ProteinsARID1A protein, humanDNA-Binding ProteinsFGFR3 protein, humanHistone DemethylasesKDM6A protein, humanKMT2D protein, humanNeoplasm ProteinsNuclear ProteinsRB1 protein, humanReceptor, Fibroblast Growth Factor, Type 3Retinoblastoma Binding ProteinsTelomeraseTERT protein, humanTP53 protein, humanTranscription FactorsTumor Suppressor Protein p53Ubiquitin-Protein LigasesAACR Project GENIEbladder cancercopy number alterationsdemographic disparitiesgenomic profilingsomatic mutationstargeted therapyurothelial carcinoma

Identifiers

PMID41373802

DOI10.3390/ijms262311653

PMCPMC12692009

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.